Company research
CODEXIS, INC.
CIK 1200375Updated Sep 24, 2026
SecurityCDXS · NASDAQ · equity
Name history
CODEXIS INC · through Jun 13, 2019
CDXS price & chart
Loading TradingView…
NASDAQ:CDXS on TradingView ↗About the company
Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® Manufacturing Platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
In the news
Codexis Announces Proposed Public Offering of Common Stock ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
424B5 filing
424B5 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 147,797,000Source | 149,011,000Source | 136,561,000Source | 250,393,000Source |
| Property, Plant and Equipment, NetUSD | 13,024,000Source | 14,197,000Source | 15,487,000Source | 22,614,000Source |
| GoodwillUSD | 2,463,000Source | 2,463,000Source | 2,463,000Source | 3,241,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 50,793,000Source | 19,264,000Source | 65,116,000Source | 113,984,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 10,036,000Source | 31,904,000Source |
| Inventory, NetUSD | 1,817,000Source | 1,799,000Source | 2,685,000Source | 2,029,000Source |
| Assets, CurrentUSD | 96,816,000Source | 98,772,000Source | 93,466,000Source | 162,894,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,626,000Source | 4,128,000Source | 5,218,000Source | 5,487,000Source |
| Operating Lease, Right-of-Use AssetUSD | 30,501,000Source | 28,700,000Source | 13,137,000Source | 39,263,000Source |
| Other Assets, NoncurrentUSD | 883,000Source | 1,019,000Source | 1,246,000Source | 350,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 97,268,000Source | 82,084,000Source | 49,946,000Source | 105,596,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 9,000Source | 8,000Source | 7,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 657,292,000Source | 629,673,000Source | 584,138,000Source | 566,081,000Source |
| Retained Earnings (Accumulated Deficit)USD | -606,780,000Source | -562,806,000Source | -497,530,000Source | -421,290,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 8,000Source | 52,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 50,529,000Source | 66,927,000Source | 86,615,000Source | 144,797,000Source |
| Liabilities and EquityUSD | 147,797,000Source | 149,011,000Source | 136,561,000Source | 250,393,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 25,317,000Source | 23,648,000Source | 35,830,000Source | 49,066,000Source |
| Operating Lease, Liability, CurrentUSD | 2,944,000Source | 2,827,000Source | 10,121,000Source | 5,360,000Source |
| Accounts Payable, CurrentUSD | 1,554,000Source | 2,838,000Source | 5,947,000Source | 3,246,000Source |
| Operating Lease, Liability, NoncurrentUSD | 30,159,000Source | 28,163,000Source | 12,243,000Source | 38,278,000Source |
| Other Liabilities, NoncurrentUSD | 1,327,000Source | 1,268,000Source | 1,233,000Source | 1,371,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,768,000Source | 6,223,000Source | 4,735,000Source | 15,279,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 78,209,000Source | 73,458,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | 11,000Source | 14,000Source | 16,000Source | 16,000Source |
| Long-term DebtUSD | 40,105,000Source | 28,905,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 40,105,000Source | 28,905,000Source | — | — |
| Short-term InvestmentsUSD | 27,416,000Source | 54,194,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 5,248,000Source | 4,946,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,624,000Source | 13,087,000Source | 9,971,000Source | 14,531,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 19,000Source | -886,000Source | 656,000Source | 869,000Source |
| Increase (Decrease) in Accounts PayableUSD | -1,286,000Source | -2,567,000Source | 2,287,000Source | 207,000Source |
| Deferred Income Tax Expense (Benefit)USD | -3,000Source | -2,000Source | 0Source | -7,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -19,376,000Source | -49,410,000Source | -52,638,000Source | 11,284,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 23,502,000Source | -56,980,000Source | -4,858,000Source | -13,578,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,471,000Source | 4,305,000Source | 4,418,000Source | 8,307,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 0Source | 0Source | 404,000Source | 1,488,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 27,928,000Source | 60,522,000Source | 8,167,000Source | -575,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 32,054,000Source | -45,868,000Source | -49,329,000Source | -2,869,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 52,883,000Source | 20,829,000Source | 66,697,000Source | 116,026,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,149,000Source | 2,566,000Source | 44,000Source | 34,000Source |
| Income Taxes Paid, NetUSD | — | 17,000Source | 194,000Source | 100,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 700,000Source | 2,000,000Source | 1,000,000Source | 1,000,000Source |
| Amortization of Debt Issuance CostsUSD | 1,305,000Source | 885,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 78,209,000Source | 73,458,000Source | — | — |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | — | 208,000Source |
| DepreciationUSD | 5,097,000Source | 4,845,000Source | 5,518,000Source | 5,402,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | 0Source | 0Source | — |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 300,000Source | 6,902,000Source | 12,215,000Source | — |
| GoodwillUSD | 2,463,000Source | 2,463,000Source | 2,463,000Source | 3,241,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 778,000Source | — |
| Income Tax Expense (Benefit)USD | 47,000Source | 34,000Source | 69,000Source | 276,000Source |
| Investment Income, InterestUSD | 2,625,000Source | 3,670,000Source | 4,172,000Source | 1,441,000Source |
| Net Income (Loss) Attributable to ParentUSD | -43,974,000Source | -65,276,000Source | -76,240,000Source | -33,592,000Source |
| Operating Lease, Impairment LossUSD | — | — | 2,997,000Source | — |
| Other Nonoperating Income (Expense)USD | -4,813,000Source | -10,393,000Source | -12,274,000Source | 124,000Source |
| Payments of Financing CostsUSD | — | — | 503,000Source | — |
| Proceeds from Issuance of Common StockUSD | 17,267,000Source | 31,319,000Source | 8,652,000Source | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | 9,897,000Source | 29,521,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 1,098,000Source | 1,384,000Source | 422,000Source | 955,000Source |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | — | 0Source | 54,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 70,387,000Source | 59,345,000Source | 70,143,000Source | 138,590,000Source |
| Cost of RevenueUSD | 9,338,000Source | 16,288,000Source | 12,809,000Source | 38,033,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 47,074,000Source | 55,148,000Source | 53,250,000Source | 52,172,000Source |
| Operating Income (Loss)USD | -41,739,000Source | -58,519,000Source | -68,069,000Source | -34,881,000Source |
| Other Nonoperating Income (Expense)USD | -4,813,000Source | -10,393,000Source | -12,274,000Source | 124,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -43,927,000Source | -65,242,000Source | -76,171,000Source | -33,316,000Source |
| Income Tax Expense (Benefit)USD | 47,000Source | 34,000Source | 69,000Source | 276,000Source |
| Net Income (Loss) Attributable to ParentUSD | -43,974,000Source | -65,276,000Source | -76,240,000Source | -33,592,000Source |
| Earnings Per Share, BasicUSD per share | -0.5Source | -0.89Source | -1.12Source | -0.51Source |
| Earnings Per Share, DilutedUSD per share | -0.5Source | -0.89Source | -1.12Source | -0.51Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 87,142,000Source | 73,408,000Source | 68,131,000Source | 65,344,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 87,142,000Source | 73,408,000Source | 68,131,000Source | 65,344,000Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 112,126,000Source | 117,864,000Source | 138,212,000Source | 173,471,000Source |
| Current Income Tax Expense (Benefit)USD | 50,000Source | 36,000Source | 69,000Source | 283,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | — | 208,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 300,000Source | 6,902,000Source | 12,215,000Source | — |
| Goodwill, Impairment LossUSD | — | 0Source | 778,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -43,908,000Source | -65,231,000Source | -76,169,000Source | -33,269,000Source |
| Investment Income, InterestUSD | 2,625,000Source | 3,670,000Source | 4,172,000Source | 1,441,000Source |
| Research and Development ExpenseUSD | 52,307,000Source | 46,263,000Source | 58,885,000Source | 80,099,000Source |
Filing attachments
d171403dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d171403dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA Completed successful equity capital raise of approximately $25 million in net proceeds REDWOOD…
Read attachment ↗d112205dex991.htm · 8-K · 2026-05-07
EX-99.1 2 d112205dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports First Quarter 2026 Financial Results Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 7, 2026 - Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturi…
Read attachment ↗d106216dex991.htm · 8-K · 2026-03-11
EX-99.1 2 d106216dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 - Codexis, Inc. (NASDAQ: CDXS), a leading provider of…
Read attachment ↗d80118dex991.htm · 8-K · 2025-11-06
EX-99.1 2 d80118dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports Third Quarter 2025 Financial Results Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., November 6, 2025 - Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financia…
Read attachment ↗d940510dex991.htm · 8-K · 2025-08-13
EX-99.1 2 d940510dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports Second Quarter 2025 Financial Results Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis ® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., August 13, 2025 - Codexis, Inc. (NASDAQ: CDXS), a leading provider of…
Read attachment ↗d949323dex991.htm · 8-K · 2025-05-14
EX-99.1 2 d949323dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports First Quarter 2025 Financial Results Secured first revenue-generating contract for ECO Synthesis ™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 - Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic soluti…
Read attachment ↗